1.World Health Organization. Global hepatitis report, 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua = 1. Accessed 1 December 2018.
2.World Health Organization. Global health sector strategy on HIV, 2016–2021. Towards ending AIDS. http://www.who.int/hiv/strategy2016–2021/ghss-hiv/en/. Accessed 1 December 2018.
3.World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV–2016.06-eng.pdf?ua = 1. Accessed 1 December 2018.
4.Pioche C, Pelat C, Larsen C, Desenclos JC, Jauffret Roustide M, Lot F, et al. Estimation de la prévalence de l’hépatite C en population générale, France métropolitaine, 2011. Numéro thématique. Hépatites B et C, données épidémiologiques récentes. Bull Epidemiol Hebd 2016:224–229.
5.Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. Journal of medical virology 2010;82:546–555.
6.Marty L, Cazein F, Lot F, Costagliola D, Supervie V, editors. Nouvelles estimations de la prévalence de l’infection à VIH. Réunion Journée mondiale de lutte contre le Sida; 2018 26/11/2018; Paris.
7.Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PloS one 2015;10:e0126920.
8.Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, et al. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver Int 2016;36:1442–1449.
9.Cazein F, Le Strat Y, Sarr A, Ramus C, Bouche N, Comboroure JC, et al. Dépistage de l’infection par le VIH en France en 2016. Numéro thématique. Journée mondiale du sida, 1er décembre 2017. Bull Epidemiol Hebd 2017:601–608.
10.Pioche C, Léon L, Vaux S, Brouard C, Lot F. Dépistage des hépatites B et C en France en 2016, nouvelle édition de l’enquête LaboHep. Bull Epidemiol Hebd 2018:188–195.
11.Haute autorité de santé. Réévaluation de la stratégie de dépistage de l’infection à VIH en France. https://www.has-sante.fr/portail/upload/docs/application/pdf/2017–03/dir2/reevaluation_de_la_strategie_depistage_vih_-_synthese_conclusions_reco.pdf. Accessed 1 December 2018.
12.Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, et al. Routine HIV screening in France: clinical impact and cost-effectiveness. PloS one 2010;5:e13132.
13.Agence nationale d’accréditation et d’évaluation en santé. Dépistage de l’hépatite C - Populations à dépister et modalités du dépistage. Recommandations du comité d’experts réuni par l’ANAES. http://www.has-sante.fr/portail/upload/docs/application/pdf/hepatite.pdf. Accessed 1 December 2018.
14.Agence nationale d’accréditation et d’évaluation en santé. Diagnostic et suivi virologiques des hépatites virales (à l’exclusion du dépistage en cas de dons de sang, d’organes ou de tissus). https://www.has-sante.fr/portail/upload/docs/application/pdf/Hepatites_virales_recos.pdf. Accessed 1 December 2018.
15.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The lancet Gastroenterology & hepatology 2018;3:383–403.
16.Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The lancet Gastroenterology & hepatology 2017;2:161–176.
17.Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The lancet Gastroenterology & hepatology 2017;2:325–336.
18.Haute autorité de santé. Prise en charge de l’hépatite C par les médicaments anti-viraux à action directe (AAD). Elargissement du périmètre de remboursement. https://www.has-sante.fr/portail/upload/docs/application/pdf/2016–12/recommandation_college_hepatite_c.pdf. Accessed 2 December 2018.
19.Haute autorité de santé. Feuille de route. Evaluation des stratégies de dépistage des personnes infectées par le VHC (volet 1). https://www.has-sante.fr/portail/upload/docs/application/pdf/2018–11/feuille_de_route_evaluation_strategies_depistage_vhc_vf_2018–11–28_15–43–5_301.pdf. Accessed 2 December 2018.
20.Ministère des Affaires sociales et de la Santé. Prise en charge thérapeutique et suivi de l’ensemble des personnes infectées par le virus de l’hépatite C. Rapport de recommandations 2016. Sous la direction du Pr Daniel Dhumeaux. Sous l’égide de l’ANRS et du CNS et avec le concours de l’AFEF. http://social-sante.gouv.fr/IMG/pdf/rapport_.pdf. Accessed 1 December 2018.
21.Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol 2018;69:785–792.
22.Lydie N, Saboni L, Gautier A, Brouard C, Chevaliez S, Barin F, et al. Innovative Approach for Enhancing Testing of HIV, Hepatitis B, and Hepatitis C in the General Population: Protocol for an Acceptability and Feasibility Study (BaroTest 2016). JMIR research protocols 2018;7:e180.
23.Richard J-B, Andler R, Gautier A, Guignard R, Leon C, Beck F. Effects of using an Overlapping Dual-Frame Design on Estimates of Health Behaviors: A French General Population Telephone Survey. J Surv Stat Methodol 2016.
24.Haziza D, Beaumont J-F. On the Construction of Imputation Classes in Surveys. International Statistical Review 2007;75:25–43.
25.El Tinge JL, Yansaneh IS. Diagnostics for formation of nonresponse adjustment cells, with an application to income nonresponse in the US Consumer Expenditure Survey. Survey methodology 1997;23:33–40.
26.Little RJ. Survey nonresponse adjustments for estimates of means. International Statistical Review/Revue Internationale de Statistique 1986:139–157.
27.Santin G, Geoffroy B, Benezet L, Delezire P, Chatelot J, Sitta R, et al. In an occupational health surveillance study, auxiliary data from administrative health and occupational databases effectively corrected for nonresponse. Journal of clinical epidemiology 2014;67:722–730.
28.World Health Organization. Global distribution of hepatitis A, B and C, 2001. Wkly Epidemiol Rec 2002;77:41–48.
29.Elliot E, Rossi M, McCormack S, McOwan A. Identifying undiagnosed HIV in men who have sex with men (MSM) by offering HIV home sampling via online gay social media: a service evaluation. Sexually transmitted infections 2016;92:470–473.
30.Seguin M, Dodds C, Mugweni E, McDaid L, Flowers P, Wayal S, et al. Self-sampling kits to increase HIV testing among black Africans in the UK: the HAUS mixed-methods study. Health technology assessment (Winchester, England) 2018;22:1–158.
31.Bhatti P, Kampa D, Alexander BH, McClure C, Ringer D, Doody MM, et al. Blood spots as an alternative to whole blood collection and the effect of a small monetary incentive to increase participation in genetic association studies. BMC medical research methodology 2009;9:76.
32.Sakhi AK, Bastani NE, Ellingjord-Dale M, Gundersen TE, Blomhoff R, Ursin G. Feasibility of self-sampled dried blood spot and saliva samples sent by mail in a population-based study. BMC cancer 2015;15:265.
33.Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, et al. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC infectious diseases 2017;17:693.
34.Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, et al. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses. BMC infectious diseases 2017;17:700.
35.Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol 2018;69:916–926.
36.Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004–2011: model-based estimation from two national cross-sectional serosurveys. Epidemiology and infection 2017;145:895–907.
37.Pillonel J, Laperche S, Boulat C, Gallian P, Gross S, Roche C. Surveillance épidémiologique des donneurs de sang, 1992–2016. http://invs.santepubliquefrance.fr/fr../Dossiers-thematiques/Populations-et-sante/Donneurs-de-sang/La-surveillance-epidemiologique-des-donneurs-de-sang-VIH-VHC-VHB-HTLV-syphilis. Accessed 2 December 2018.
38.Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. [Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013;56:707–715.
39.Vaux S, Laporal S, Pioche C, Brouard C, Lot F. Hépatites B et C, dernières données épidémiologiques. https://solidarites-sante.gouv.fr/IMG/pdf/1-presentation_s_vaux.pdf. Accessed 1 December 2018.
40.Brouard C, Gautier A, Saboni L, Jestin C, Semaille C, Beltzer N. Hepatitis B knowledge, perceptions and practices in the French general population: the room for improvement. BMC public health 2013;13:576.
41.Brouard C, Gautier A, Vaux S, Richard J-B. Sentiment d’information et pratiques déclarées de dépistage vis-à-vis des hépatites B et C en population générale ultramarine. Enquête Baromètre santé DOM 2014. Bull Epidemiol Hebd 2018:204–209.
42.Origer A, Schmit JC. Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence. Journal of epidemiology and community health 2012;66:64–68.
43.Boyd A, Gozlan J, Carrat F, Rougier H, Girard PM, Lacombe K, et al. Self-reported patient history to assess hepatitis B virus serological status during a large screening campaign. Epidemiology and infection 2018:1–8.